Browsing publications by Dr Yvette Drew

Newcastle AuthorsTitleYearFull text
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Dr Yvette Drew
Dr Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Dr Yvette Drew
A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
The development of PARP inhibitors in ovarian cancer: from bench to bedside2015
Dr Yvette Drew
Ajay Gupta
Professor Ruth Plummer
A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors2013
Dr Nicola Cresti
Dr Yvette Drew
Professor Ruth Plummer
A phase I study of oral rucaparib in combination with carboplatin2013
Bojidar Goranov
Dr Yvette Drew
Jonathon Graham
Dr Rachel Pearson
Academic opportunities within clinical oncology training2013
Dr Jane Margetts
Dr Yvette Drew
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
et al.
Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)2013
Dr Jane Margetts
Dr Yvette Drew
Professor Ruth Plummer
Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors2013
123